{"doi":"10.1371/journal.ppat.1008365","title":"B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection","abstract":null,"journal":"PLOS Pathogens","year":2020,"id":606196,"datarank":0.5641800173540344,"base_score":3.7612001156935624,"endowment":3.7612001156935624,"self_citation_contribution":0.5641800173540344,"citation_network_contribution":0.0,"self_endowment_contribution":0.5641800173540344,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":42,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":488612,"name":"Shane M. Huebner","orcid":"0000-0003-2045-1688","position":1,"is_corresponding":false},{"id":428774,"name":"Makoto Ohashi","orcid":"0009-0006-5134-6038","position":2,"is_corresponding":false},{"id":428776,"name":"Jillian A. Bristol","orcid":"0000-0001-6109-8126","position":3,"is_corresponding":false},{"id":690781,"name":"Bayleigh E. Benner","orcid":"0000-0002-6266-5740","position":4,"is_corresponding":false},{"id":1556001,"name":"Elizabeth A. Barlow","orcid":"0000-0002-2269-1629","position":5,"is_corresponding":false},{"id":1556002,"name":"Gail L. Turk","orcid":"0000-0002-8987-6943","position":6,"is_corresponding":false},{"id":428777,"name":"Scott E. Nelson","orcid":"0000-0003-0084-1355","position":7,"is_corresponding":false},{"id":903032,"name":"Dana C. Baiu","orcid":"0000-0001-7542-5300","position":8,"is_corresponding":false},{"id":488613,"name":"Nicholas Van Sciver","orcid":"0000-0001-7967-6895","position":9,"is_corresponding":false},{"id":336005,"name":"Erik A. Ranheim","orcid":"0000-0002-5786-9327","position":10,"is_corresponding":false},{"id":338814,"name":"Jenny E. Gumperz","orcid":"0000-0003-1852-2192","position":11,"is_corresponding":false},{"id":461939,"name":"Nathan M. Sherer","orcid":"0000-0001-9974-236X","position":12,"is_corresponding":false},{"id":721997,"name":"Paul J. Farrell","orcid":"0000-0002-6754-9351","position":13,"is_corresponding":false},{"id":1556003,"name":"Eric C. Johannsen","orcid":null,"position":14,"is_corresponding":false},{"id":428779,"name":"Shannon C. Kenney","orcid":"0000-0002-9655-6526","position":15,"is_corresponding":false},{"id":428773,"name":"James C. Romero-Masters","orcid":"0000-0001-6871-0568","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection","abstract":"Humans are infected with two distinct strains (Type 1 (T1) and Type 2 (T2)) of Epstein-Barr virus (EBV) that differ substantially in their EBNA2 and EBNA 3A/B/C latency genes and the ability to transform B cells in vitro. While most T1 EBV strains contain the \"prototype\" form of the BZLF1 immediate-early promoter (\"Zp-P\"), all T2 strains contain the \"Zp-V3\" variant, which contains an NFAT binding motif and is activated much more strongly by B-cell receptor signalling. Whether B cells infected with T2 EBV are more lytic than cells infected with T1 EBV is unknown. Here we show that B cells infected with T2 EBV strains (AG876 and BL5) have much more lytic protein expression compared to B cells infected with T1 EBV strains (M81, Akata, and Mutu) in both a cord blood-humanized (CBH) mouse model and EBV-transformed lymphoblastoid cell lines (LCLs). Although T2 LCLs grow more slowly than T1 LCLs, both EBV types induce B-cell lymphomas in CBH mice. T1 EBV strains (M81 and Akata) containing Zp-V3 are less lytic than T2 EBV strains, suggesting that Zp-V3 is not sufficient to confer a lytic phenotype. Instead, we find that T2 LCLs express much higher levels of activated NFATc1 and NFATc2, and that cyclosporine (an NFAT inhibitor) and knockdown of NFATc2 attenuate constitutive lytic infection in T2 LCLs. Both NFATc1 and NFATc2 induce lytic EBV gene expression when combined with activated CAMKIV (which is activated by calcium signaling and activates MEF2D) in Burkitt Akata cells. Together, these results suggest that B cells infected with T2 EBV are more lytic due to increased activity of the cellular NFATc1/c2 transcription factors in addition to the universal presence of the Zp-V3 form of BZLF1 promoter.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"32059024","pmcid":"PMC7046292","openalex_id":null,"authors":[],"funders":[{"funder_name":"Foundation for the National Institutes of Health","grant_id":"CA232616-02","title":null},{"funder_name":"Foundation for the National Institutes of Health","grant_id":"AI147060-01A1","title":null},{"funder_name":"Foundation for the National Institutes of Health","grant_id":"CA229673-01A1","title":null},{"funder_name":"Foundation for the National Institutes of Health","grant_id":"CA022443-42","title":null},{"funder_name":"Foundation for the National Institutes of Health","grant_id":"CA014520-45","title":null},{"funder_name":"Foundation for the National Institutes of Health","grant_id":"CA009135","title":null},{"funder_name":"Medical Research Council","grant_id":"MR/S022597/1","title":"Functional investigation of Epstein-Barr virus infection and latent gene function using natural variants found in normal infections and cancer cells"},{"funder_name":"NCI NIH HHS","grant_id":"P30 CA014520","title":null},{"funder_name":"NCI NIH HHS","grant_id":"R01 CA229673","title":null},{"funder_name":"NIAID NIH HHS","grant_id":"R01 AI147060","title":null},{"funder_name":"NCI NIH HHS","grant_id":"P01 CA022443","title":null},{"funder_name":"NCI NIH HHS","grant_id":"R01 CA232616","title":null},{"funder_name":"NCI NIH HHS","grant_id":"T32 CA009135","title":null},{"funder_name":"National Institutes of Health","grant_id":"5R01CA229673-03","title":"Role of EBV Lytic Infection in Viral Tumorigenesis"},{"funder_name":"National Institutes of Health","grant_id":"3T32CA009135-13S1","title":"PREDOCTORAL TRAINING IN EXPERIMENTAL ONCOLOGY"},{"funder_name":"National Institutes of Health","grant_id":"2P01CA022443-31","title":"Mechanisms of Reactivation of Epstein-Barr Virus from Latency to Lytic Replicatio"},{"funder_name":"National Institutes of Health","grant_id":"3P01CA022443-43S1","title":"Developing and Applying a Safe, Tractable Derivative of SARS-CoV-2"},{"funder_name":"National Institutes of Health","grant_id":"5R01AI147060-05","title":"Effects of EBV Type on Viral Reactivation"},{"funder_name":"National Institutes of Health","grant_id":"1R01CA232616-01","title":"EBV LMP1/LMP2A Proteins Promote Hodgkin-like Lymphomas in Humanized Mice"},{"funder_name":"National Institutes of Health","grant_id":"5P30CA014520-18","title":"CANCER CENTER SUPPORT"},{"funder_name":"National Institutes of Health","grant_id":"5R01AI147060-02","title":"Effects of EBV Type on Viral Reactivation"}],"total_grants":21,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://storage.googleapis.com/plos-corpus-prod/10.1371/journal.ppat.1008365/2/ppat.1008365.pdf?X-Goog-Algorithm=GOOG4-RSA-SHA256&X-Goog-Credential=wombat-sa%40plos-prod.iam.gserviceaccount.com%2F20210219%2Fauto%2Fstorage%2Fgoog4_request&X-Goog-Date=20210219T183039Z&X-Goog-Expires=3600&X-Goog-SignedHeaders=host&X-Goog-Signature=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","host_type":"publisher"},{"url":"https://dx.plos.org/10.1371/journal.ppat.1008365","host_type":"publisher"},{"url":"https://doaj.org/article/ec69057eebe34560b5bc126ef97ce47f","host_type":"repository"},{"url":"https://figshare.com/articles/dataset/B_cells_infected_with_Type_2_Epstein-Barr_virus_EBV_have_increased_NFATc1_NFATc2_activity_and_enhanced_lytic_gene_expression_in_comparison_to_Type_1_EBV_infection/11857260","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7046292","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC7046292","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC7046292?pdf=render","host_type":"Europe_PMC"},{"url":"https://doi.org/10.1371/journal.ppat.1008365","host_type":""},{"url":"https://pubmed.ncbi.nlm.nih.gov/32059024","host_type":""},{"url":"http://dx.doi.org/10.1371/journal.ppat.1008365","host_type":""},{"url":"https://dx.doi.org/10.1371/journal.ppat.1008365","host_type":""},{"url":"https://doi.org/https://doi.org/10.1371/journal.ppat.1008365","host_type":""}],"fields_of_study":["0301 basic medicine","03 medical and health sciences","0303 health sciences"],"mesh_terms":["B-Lymphocytes","Cell Line","Animals","Humans","Mice","Herpesvirus 4, Human","Epstein-Barr Virus Infections","DNA-Binding Proteins","Trans-Activators","Transcription Factors","Viral Proteins","Epstein-Barr Virus Nuclear Antigens","Virus Latency","Virus Activation","Gene Expression","Gene Expression Regulation, Viral","NFATC Transcription Factors","Promoter Regions, Genetic"],"keywords":["Gene Expression Regulation, Viral","570","Epstein-Barr Virus Infections","Herpesvirus 4, Human","QH301-705.5","610","Gene Expression","Cell Line","Mice","Viral Proteins","Animals","Humans","Biology (General)","Promoter Regions, Genetic","B-Lymphocytes","NFATC Transcription Factors","RC581-607","Virus Latency","DNA-Binding Proteins","Epstein-Barr Virus Nuclear Antigens","Trans-Activators","Virus Activation","Immunologic diseases. Allergy","Research Article","Transcription Factors"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"gen"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T04:04:32.841410Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}